Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We’re driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... About us

... Our unique commitment to pain

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives & Grants

... Our positions

We believe that success comes from close collaborations founded on a shared vision to develop innovative medicines for patients that suffer from diseases with high unmet needs.

... Partnering

We strengthen and develop our core markets Europe, North America, Latin America and Asia through acquisitions, asset deals, in-licensing, commercialization and distribution deals.

... Areas of interest

... Public Private Partnerships

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Our products

Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).

Active ingredient / Technology	Brand name, examples	Indication range, EU as example¹
Capsaicin	Qutenza^TM	Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain
Lidocaine	Versatis™*	Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults
Zolmitriptan	Zomig™ AscoTop™	FCT and ODT: In adults aged 18 years and older for acute treatment of migraine headache with or without aura Nasal Spray: In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura and in adults for the treatment of cluster headache
Esomeprazole	Nexium™	Tablets: Indicated in adolescents from the age of 12 years and in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) Indicated in adults for: In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers Patients requiring continued NSAID therapy - Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers Treatment of Zollinger Ellison Syndrome In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori IV: Indicated in children and adolescents aged 1-18 years and in adults for: Gastric antisecretory treatment when the oral route is not possible, such as: · gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux Indicated in adults for: Gastric antisecretory treatment when the oral route is not possible, such as: · healing of gastric ulcers associated with NSAID therapy. · prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers Indicated in children and adolescents aged 1-18 years for: Gastric antisecretory treatment when the oral route is not possible, such as: · gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux Granules for oral suspension: Children 1-11 years old: Gastroesophageal Reflux Disease (GERD) - treatment of endoscopically proven erosive reflux esophagitis - symptomatic treatment of gastroesophageal reflux disease (GERD) Children over 4 years of age: In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori Adults and adolescents from the age of 12 years: Reference is made to the Nexium gastro-resistant tablet SmPC Nexium oral suspension may also be used by patients having difficulty swallowing dispersed Nexium gastro-resistant tablets
Fixed-dose combination of Esomeprazole and Naproxen	Vimovo™	Symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
Proprietary hot melt extrusion (HME) technology platform	Intac™	Technology to raise barriers to non-oral routes of abuse of active pharmaceutical ingredients (APIs) with abuse potential

¹Status: March 2019.

Overview of medication that contains an opioid mechanism of action

Our products

We have been striving to provide solutions for patients with large unmet medical needs for over five decades. If you are a healthcare professional, find out what we have achieved to date by exploring our product portfolio and visiting the Grünenthal Health website.

... Visit Grünenthal Health